The influence of dental metal alloys on cell proliferation and fibronectin arrangement in human fibroblast cultures.
The biocompatibility of six single-phase dental metal alloys was studied by determining cell proliferation rates correlated to the arrangement of fibronectin (FN) in fibroblast cultures. Immunocytochemical methods were used to detect cell proliferation by 5-bromodeoxyuridine (BrdU) incorporation, and FN organization [i.e. diffuse in the extracellular matrix and organized in fibrils or in focal adhesions (FA)] in human fibroblast cultures. Cell proliferation rates were related to FN arrangement and in particular a higher percentage of cells in the S-phase was related to a predominance of FA. The greatest difference in behaviour compared to that of the controls was detected after 120 and 168 hr: at these times, as well as at previous ones, the alloy with the highest Au content seemed the most biocompatible among those tested, as it behaved in a very similar way to the controls. In contrast, fibroblasts exposed to the other five alloys showed different behaviours from the controls. It is assumed that a correlation exists between FN organization and the percentage of BrdU-positive cells, and that these features vary in the presence of different alloys. The observation of FN arrangement together with cell proliferation rates could be another useful tool in determining the biocompatibility of dental metal alloys.
Grill
V
V
Department of Human Morphology, University of Trieste, Italy.
Sandrucci
M A
MA
Basa
M
M
Di Lenarda
R
R
Dorigo
E
E
Narducci
P
P
Martelli
A M
AM
Delbello
G
G
Bareggi
R
R
D000963:Antimetabolites; D001672:Biocompatible Materials / Q000494:pharmacology; D001973:Bromodeoxyuridine; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003300:Copper / Q000494:pharmacology; D003722:Dental Alloys / Q000494:pharmacology*; D005109:Extracellular Matrix / Q000378:metabolism / Q000648:ultrastructure; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D005353:Fibronectins / Q000378:metabolism / Q000648:ultrastructure*; D019084:Fluorescent Antibody Technique, Indirect; D005708:Gallium / Q000494:pharmacology; D006047:Gold Alloys / Q000494:pharmacology; D006801:Humans; D007150:Immunohistochemistry; D007204:Indium / Q000494:pharmacology; D008670:Metals / Q000494:pharmacology*; D010165:Palladium / Q000494:pharmacology; D010984:Platinum / Q000494:pharmacology; D016196:S Phase / Q000187:drug effects; D012834:Silver / Q000494:pharmacology; D013997:Time Factors; D014001:Tin / Q000494:pharmacology
D000963:Antimetabolites; D001672:Biocompatible Materials; D003722:Dental Alloys; D005353:Fibronectins; D006047:Gold Alloys; D008670:Metals; D007204:Indium; D012834:Silver; D010984:Platinum; D010165:Palladium; D014001:Tin; D003300:Copper; D005708:Gallium; D001973:Bromodeoxyuridine